ALISO VIEJO, Calif.—ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, has announced that it has closed a Series C financing raising gross proceeds of approximately $40 million. The financing was led by a new investor along with strong support from current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision, an ophthalmology investment platform supported by KKR. Proceeds from this round of financing will ensure the continued advancement of clinical, regulatory and commercial milestones of the company's ViaLase Laser.

If approved, the ViaLase Laser will be the first femtosecond laser used for the treatment of primary open angle glaucoma (POAG), according to the company.

"ViaLase's innovative approach to glaucoma management has the potential to elevate the standard of care for glaucoma patients around the world," said Jim Adox, executive managing director, Venture Investors. "We have strongly believed in ViaLase's proven leadership, brilliant team, and pioneering technology since we wrote the first seed check to back the team."

"The strong support from our investors validates the potential of the ViaLase Laser to enhance the current treatment paradigm for the millions of patients living with glaucoma," said Tibor Juhasz, PhD, founder and chief executive officer, ViaLase, Inc. "We are preparing to embark on a new phase in our company's evolution—commercialization—and are incredibly fortunate to have the support, resources, financial backing and counsel of such a high-caliber group of investors."